Incidence of chemotherapy-induced severe neutropenia in nadir period in gynecologic cancer patients receiving Carboplatin and Paclitaxel
Article Sidebar
Main Article Content
Abstract
Objectives: This study aimed to determine the incidence of chemotherapy-induced severe neutropenia in the nadir period among gynecologic cancer patients receiving Carboplatin and Paclitaxel.
Materials and methods: This prospective cohort study recruited 150 gynecologic cancer patients receiving Carboplatin and Paclitaxel. Complete blood counts (CBC) were collected before receiving chemotherapy and during the nadir period of each cycle, followed until discontinuation of the regimen or completion of six cycles, to evaluate the incidence of severe neutropenia.
Results: A total of 793 cycles were analyzed in 150 patients. Severe neutropenia occurred in 366 cycles and 111 patients during the nadir periods, with 46.2% per cycle and 74.0% per patient, respectively. The incidence tended to increase in later cycles. The prior use of granulocyte-colony stimulating factor (G-CSF) was 2.9%. The incidence of febrile neutropenia was 4.7%. No additional treatment for severe neutropenia was provided in 80.2%. Postmenopausal status and an initial white blood cell count (WBC) below 7000 cells/μL were significant risk factors for severe neutropenia. Additionally, an initial absolute neutrophil count (ANC) below 5000 cells/μL was a significant risk factor for febrile neutropenia.
Conclusion: Despite severe neutropenia being relatively common during the nadir periods, the majority did not receive further management and subsequently recovered. Furthermore, the incidence of febrile neutropenia was low. Therefore, evaluation of ANC in nadir periods should be selectively performed in patients at risk for severe and febrile neutropenia.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778-789.
Akram T, Muggia FM, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol. 2005;192(4):1235-1240.
Burke TW, Markman M, Kavanagh JJ, Morris M, Levenback C, Tornos C. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol. 1993;51(2):255-258.
Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: The Cleveland Clinic experience. Semin Oncol. 1997;24(1 Suppl 2):S2-15-18.
Alberts DS, Hannigan EV, O’Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-717.
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051.
Markman J, Zanotti K, Webster K, Belinson J, Peterson G, Kulp B, et al. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol. 2004;92(2):592-595.
Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008;109(2):250-254.
Guastalla JP, Pujade-Lauraine E, Weber B, Cure H, Orfeuvre H, Mousseau M, et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma: A multicenter GINECO phase II study. Ann Oncol. 1998;9(1):37-43.
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841-3850.
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2015;26(10):1054-1060.
Laskey RA, Poniewierski MS, Lopez MA, Hanna RK, Secord AA, Gehrig PA, et al. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol. 2012;125(3):625-630.
Pimsi P, Therasakvichya S, Saengsukkasemsak N, Laocharoenkeat A. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand. Eur J Gynaecol Oncol. 2018;39(2):242-246.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, et al. Myeloid growth factors, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(12):1520-1541.
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer. 2011;47(1):8-32.